{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:39:57Z","timestamp":1790264397084,"version":"4.1.0"},"reference-count":34,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung hyperinflation in COPD adversely affects cardiac function and may influence autonomic nervous system activity. The onset of cardiac improvement with dual bronchodilator therapy remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomised, placebo-controlled, investigator-blinded, mechanistic, single-dose crossover trial with an open-label 2-week extension we assessed tiotropium\/olodaterol (T\/O) effects on cardiopulmonary function and muscle sympathetic nerve activity (MSNA) in hyperinflated COPD patients. 32 participants received saline (placebo) and T\/O (5\u2005\u00b5g\/5\u2005\u00b5g) in a crossover design, followed by 14\u2005days of open-label T\/O. The primary end-point was change in left ventricular end-diastolic volume index (LV-EDVi) measured by magnetic resonance imaging (MRI). Secondary assessments included pulmonary function tests, MSNA measurements and advanced lung imaging including\n                      <jats:sup>129<\/jats:sup>\n                      Xe-MRI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      Single-dose T\/O significantly increased LV-EDVi relative to placebo (3.25\u2005mL\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      ; 95% CI 0.95 to 5.56), driven partly by a decrease under placebo. Compared with baseline, T\/O's acute LV-EDVi gain was minimal, yet it reached significance at 14\u2005days (4.70\u2005mL\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      ; 95% CI 1.75 to 7.65). Pulmonary parameters, in contrast, showed immediate improvement, with a marked reduction in residual volume (\u22120.67\u2005L; 95% CI \u22120.82 to \u22120.51) after a single dose. MSNA demonstrated a nonsignificant numerical rise post single-dose T\/O. No serious adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>T\/O rapidly improves pulmonary function in hyperinflated COPD patients, but significant cardiac benefits seem to require sustained therapy. These results underscore the importance of continued dual bronchodilator therapy to achieve cardiovascular improvements. The nonsignificant rise in MSNA after a single dose suggests minimal immediate effect on sympathetic activity; further studies are necessary to evaluate long-term autonomic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01282-2025","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:35:12Z","timestamp":1769776512000},"page":"01282-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute and 14-day effects of tiotropium\/olodaterol on cardiopulmonary function in COPD"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8953-9628","authenticated-orcid":false,"given":"Thomas","family":"Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-1636","authenticated-orcid":false,"given":"Nadja","family":"Stru\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-0902","authenticated-orcid":false,"given":"Ren\u00e9","family":"Pflock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-5585","authenticated-orcid":false,"given":"Karsten","family":"Heusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-9808","authenticated-orcid":false,"given":"Agilo L.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-1841","authenticated-orcid":false,"given":"Andreas","family":"Voskrebenzev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8851-1849","authenticated-orcid":false,"given":"Lea","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-4904","authenticated-orcid":false,"given":"Till F.","family":"Kaireit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2490-0583","authenticated-orcid":false,"given":"Philipp","family":"Badorrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-1187","authenticated-orcid":false,"given":"Jens","family":"Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-6909","authenticated-orcid":false,"given":"Stefan","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-0706","authenticated-orcid":false,"given":"Jens","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-6948","authenticated-orcid":false,"given":"Jens","family":"Vogel-Claussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-6186","authenticated-orcid":false,"given":"Jens M.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026070608551485000_12.3.01282-2025.1","doi-asserted-by":"crossref","first-page":"20415","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"2026070608551485000_12.3.01282-2025.2","unstructured":"World Health Organization (WHO). The top 10 causes of death. Date last updated: 7 August 2024. Date last accessed: 9 February 2025. www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"2026070608551485000_12.3.01282-2025.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00133805"},{"key":"2026070608551485000_12.3.01282-2025.4","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2810"},{"key":"2026070608551485000_12.3.01282-2025.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2245"},{"key":"2026070608551485000_12.3.01282-2025.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808836"},{"key":"2026070608551485000_12.3.01282-2025.7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.rmed.2018.02.011","article-title":"Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling","volume":"137","author":"Alter","year":"2018","journal-title":"Respir Med"},{"key":"2026070608551485000_12.3.01282-2025.8","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.2147\/COPD.S145599","article-title":"Hyperinflated lungs compress the heart during expiration in COPD patients: a new finding on dynamic-ventilation computed tomography","volume":"12","author":"Xu","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551485000_12.3.01282-2025.9","first-page":"215","article-title":"Autonomic dysfunction in patients with chronic obstructive pulmonary disease (COPD)","volume":"2","author":"van Gestel","year":"2010","journal-title":"J Thorac Dis"},{"key":"2026070608551485000_12.3.01282-2025.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-013-9544-7"},{"key":"2026070608551485000_12.3.01282-2025.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.5.3618"},{"key":"2026070608551485000_12.3.01282-2025.12","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) . 2025 GOLD Report: Global Strategy for Prevention, Diagnosis and Management of COPD. Date last accessed: 5 June 2025. https:\/\/goldcopd.org\/2025-gold-report\/"},{"key":"2026070608551485000_12.3.01282-2025.13","doi-asserted-by":"publisher","DOI":"10.1080\/15412550902724073"},{"key":"2026070608551485000_12.3.01282-2025.14","first-page":"CD008989","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","volume":"2015","author":"Farne","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070608551485000_12.3.01282-2025.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2010.03.003"},{"key":"2026070608551485000_12.3.01282-2025.16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2147\/COPD.S91684","article-title":"Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial","volume":"10","author":"Santus","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2026070608551485000_12.3.01282-2025.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201508-1647OC"},{"key":"2026070608551485000_12.3.01282-2025.18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","article-title":"Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial","volume":"6","author":"Hohlfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026070608551485000_12.3.01282-2025.19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.201805-0995OC","article-title":"Effect of indacaterol\/glycopyrronium on pulmonary perfusion and ventilation in hyperinflated patients with chronic obstructive pulmonary disease (CLAIM). A double-blind, randomized, crossover trial","volume":"199","author":"Vogel-Claussen","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070608551485000_12.3.01282-2025.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2026070608551485000_12.3.01282-2025.21","doi-asserted-by":"crossref","unstructured":"Smith HJ , Reinhold P , Goldman MD . Forced oscillation technique and impulse oscillometry. In: Gosselink R, Stam H, eds. Lung Function Testing (ERS Monograph). Sheffield, European Respiratory Society, 2005; pp. 72\u2013105. doi:10.1183\/1025448x.00031005","DOI":"10.1183\/1025448x.00031005"},{"key":"2026070608551485000_12.3.01282-2025.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005"},{"key":"2026070608551485000_12.3.01282-2025.23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034905"},{"key":"2026070608551485000_12.3.01282-2025.24","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/mrm.28264","article-title":"Investigating short-time diffusion of hyperpolarized 129 Xe in lung air spaces and tissue: a feasibility study in chronic obstructive pulmonary disease patients","volume":"84","author":"Kern","year":"2020","journal-title":"Magn Reson Med"},{"key":"2026070608551485000_12.3.01282-2025.25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/jmri.29778","article-title":"Functional pulmonary imaging","volume":"62","author":"Kern","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"2026070608551485000_12.3.01282-2025.26","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1038\/s41598-019-40343-w","article-title":"Ultrafine particles and ozone perturb norepinephrine clearance rather than centrally generated sympathetic activity in humans","volume":"9","author":"Heusser","year":"2019","journal-title":"Sci Rep"},{"key":"2026070608551485000_12.3.01282-2025.27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jamp.2024.0032","article-title":"Assessing human lung pharmacokinetics using exhaled breath particles","volume":"38","author":"Holz","year":"2025","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2026070608551485000_12.3.01282-2025.28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest package: tests in linear mixed effects models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J Stat Soft"},{"key":"2026070608551485000_12.3.01282-2025.29","doi-asserted-by":"publisher","DOI":"10.2307\/2684063"},{"key":"2026070608551485000_12.3.01282-2025.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000741"},{"key":"2026070608551485000_12.3.01282-2025.31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.resp.2016.05.014","article-title":"Short-term cardiovascular and autonomic effects of inhaled salbutamol","volume":"231","author":"Edgell","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"key":"2026070608551485000_12.3.01282-2025.32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.6.2803"},{"key":"2026070608551485000_12.3.01282-2025.33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study","volume":"178","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026070608551485000_12.3.01282-2025.34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-4-9"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01282-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:56:00Z","timestamp":1783353360000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01282-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01282-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01282-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}